Brand name: Eligard 1 Month TM
Listen to the Pronunciation:
Active ingredients: leuprorelin
What it is used for
ELIGARD 7.5mg 1 month, ELIGARD 22.5mg 3 month, ELIGARD 30mg 4 month and ELIGARD 45mg 6 month are indicated for the:, Palliative treatment of advanced prostate cancer., Treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1
How to take it
This medicine is a pack that contains more than one part.
Part 1: Injection, modified release
A white to off-white powder. Substantially free of foreign matter with no evidence of meltback.
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
Part 2: Injection, modified release
Light tan to tan clear viscous solution. May contain air bubbles but is free from visible particles and foreign matter.
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Storage instructions
- Store below 8 degrees Celsius (refrigerate)
- Refrigerate
- Shelf lifetime is 2 Years.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient leuprorelin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme